Royalty Pharma
RPRX
RPRX
318 hedge funds and large institutions have $12.1B invested in Royalty Pharma in 2022 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 126 increasing their positions, 88 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
2.27% more ownership
Funds ownership: 66.85% → 69.12% (+2.3%)
1% less capital invested
Capital invested by funds: $12.2B → $12.1B (-$159M)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Holders
318
Holding in Top 10
8
Calls
$77.9M
Puts
$15.1M
Top Buyers
| 1 | +$281M | |
| 2 | +$97.3M | |
| 3 | +$87.5M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84.3M |
| 5 |
Swedbank
Stockholm,
Sweden
|
+$36.1M |
Top Sellers
| 1 | -$343M | |
| 2 | -$59.8M | |
| 3 | -$54.5M | |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$49.7M |
| 5 |
MAMU
Marathon Asset Management (UK)
London,
United Kingdom
|
-$35.8M |